Cookies help to improve your website experience and provide secure services. Some cookies are essential for security and login functionalities, others enable easier use and convenient support. You can revoke your decision at any time.
Injeq is a medical technology company from Finland that has developed a smart needle for lumbar punctures. The needle can be inserted into the spinal cord with high precision and warns as soon as it comes into contact with spinal fluid. This is relevant for cancer patients, for example, as otherwise cancer cells can enter the central nervous system from the bloodstream.
The crowd has been supporting Injeq since 2017 as the company conquers and revitalises the medical technology market with their Smart Needle. The funding was used to successfully complete important studies needed for market approval. In 2021, the Smart Needle was officially certified.
In three funding rounds, investors were able to participate directly in the company's progress in the form of shares. In total, more than 1,600 investors participated, investing over €5.3 million. In the fourth funding round in March 2022, Injeq issued a convertible bond. Within 7 days, the company raised 3.25 million euros.
"We would like to sincerely thank all investors who have supported us for the last 5 years and believed in the IQ Needle since the beginning!"
Tommi Rasila, Dr. Tech. Chairman of the Board